Conjugation to an antifibrin monoclonal antibody enhances the fibrinolytic potency of tissue plasminogen activator in vitro
- PMID: 3130094
- DOI: 10.1021/bi00404a012
Conjugation to an antifibrin monoclonal antibody enhances the fibrinolytic potency of tissue plasminogen activator in vitro
Abstract
Tissue plasminogen activator (tPA) was covalently linked by disulfide bonds to a monoclonal antibody specific for the amino terminus of the beta chain of fibrin (antibody 59D8). The activity of the tPA-59D8 conjugate was compared with that of tPA, urokinase (UK), and a UK-59D8 conjugate. For lysis of fibrin monomer, tPA was 10 times as potent as UK, whereas both UK-59D8 and tPA-59D8 conjugates were 100 times as potent as UK and 10 times as potent as tPA. Conjugation of tPA or UK to antibody 59D8 produced a 3.2-4.5-fold enhancement in clot lysis in human plasma over that of the respective unconjugated plasminogen activator. However, the UK-59D8 conjugate was only as potent as tPA alone. Antibody-conjugated tPA or UK consumed less fibrinogen, alpha 2-antiplasmin, and plasminogen than did the unconjugated activators, at equipotent fibrinolytic concentrations. Antibody targeting thus appears to increase the concentration of tPA in the vicinity of a fibrin deposit, which thereby leads to enhanced fibrinolysis.
Similar articles
-
Antibody-enhanced thrombolysis: targeting of tissue plasminogen activator in vivo.Proc Natl Acad Sci U S A. 1987 Nov;84(21):7659-62. doi: 10.1073/pnas.84.21.7659. Proc Natl Acad Sci U S A. 1987. PMID: 3118374 Free PMC article.
-
Conjugation to antifibrin Fab' enhances fibrinolytic potency of single-chain urokinase plasminogen activator.Circulation. 1990 Jun;81(6):1974-80. doi: 10.1161/01.cir.81.6.1974. Circulation. 1990. PMID: 2111744
-
Antibody-directed fibrinolysis. An antibody specific for both fibrin and tissue plasminogen activator.J Biol Chem. 1989 Jan 15;264(2):944-8. J Biol Chem. 1989. PMID: 2492021
-
Hybrid molecules: insights into plasminogen activator function.Mol Biol Med. 1991 Apr;8(2):245-55. Mol Biol Med. 1991. PMID: 1806766 Review.
-
Remaining perspectives of mutant and chimeric plasminogen activators.Ann N Y Acad Sci. 1992 Dec 4;667:357-64. doi: 10.1111/j.1749-6632.1992.tb51636.x. Ann N Y Acad Sci. 1992. PMID: 1309056 Review.
Cited by
-
Thrombolytic agents in development.Drugs. 1995 Jul;50(1):29-42. doi: 10.2165/00003495-199550010-00003. Drugs. 1995. PMID: 7588087 Review.
-
[Antibody mediated thrombolysis. A new therapeutic principle].Klin Wochenschr. 1989 Jul 3;67(13):651-8. doi: 10.1007/BF01718025. Klin Wochenschr. 1989. PMID: 2502649 Review. German.
-
New strategies in the development of thrombolytic agents.Blut. 1988 Oct;57(4):147-62. doi: 10.1007/BF00319543. Blut. 1988. PMID: 3139109 Review.
-
Cardiovascular therapies in the 1990s. An overview.Drugs. 1991 Mar;41(3):345-57. doi: 10.2165/00003495-199141030-00003. Drugs. 1991. PMID: 1711442 Review.
-
Targeted thrombolysis by magnetoacoustic particles in photothrombotic stroke model.Biomater Res. 2022 Oct 22;26(1):58. doi: 10.1186/s40824-022-00298-y. Biomater Res. 2022. PMID: 36273198 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Other Literature Sources